SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages

Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib

(1) Spataro, Vito a

a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; HEPATOMEGALY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIVER CIRRHOSIS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79951980344 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2010.30.5359 Document Type: Article

Times cited : (16)

References (6)

1
- 36348968931
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
- DOI 10.1182/blood-2007-03-080689
- Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007 (Pubitemid 350159618)
- (2007) Blood , vol.110 , Issue.10 , pp. 3540-3546
- Kantarjian, H.M.¹ Giles, F.² Gattermann, N.³ Bhalla, K.⁴ Alimena, G.⁵ Palandri, F.⁶ Ossenkoppele, G.J.⁷ Nicolini, F.-E.⁸ O'Brien, S.G.⁹ Litzow, M.¹⁰ Bhatia, R.¹¹ Cervantes, F.¹² Haque, A.¹³ Shou, Y.¹⁴ Resta, D.J.¹⁵ Weitzman, A.¹⁶ Hochhaus, A.¹⁷ Le, C.P.¹⁸

2
- 74549214984
- Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study
- Yin OQ, Gallagher N, Tanaka C, et al: Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study. Clin Ther 31:2459-2469, 2009
- (2009) Clin Ther , vol.31 , pp. 2459-2469
- Yin, O.Q.¹ Gallagher, N.² Tanaka, C.³

3
- 33745086350
- Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
- DOI 10.1056/NEJMoa055104
- Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006 (Pubitemid 43882350)
- (2006) New England Journal of Medicine , vol.354 , Issue.24 , pp. 2542-2551
- Kantarjian, H.¹ Giles, F.² Wunderle, L.³ Bhalla, K.⁴ O'Brien, S.⁵ Wassmann, B.⁶ Tanaka, C.⁷ Manley, P.⁸ Rae, P.⁹ Mietlowski, W.¹⁰ Bochinski, K.¹¹ Hochhaus, A.¹² Griffin, J.D.¹³ Hoelzer, D.¹⁴ Albitar, M.¹⁵ Dugan, M.¹⁶ Cortes, J.¹⁷ Alland, L.¹⁸ Ottmann, O.G.¹⁹

4
- 38949178846
- Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
- DOI 10.1182/blood-2007-07-103523
- Hochhaus A, Druker B, Sawyers C, et al: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111:1039-1043, 2008 (Pubitemid 351213381)
- (2008) Blood , vol.111 , Issue.3 , pp. 1039-1043
- Hochhaus, A.¹ Druker, B.² Sawyers, C.³ Guilhot, F.⁴ Schiffer, C.A.⁵ Cortes, J.⁶ Niederwieser, D.W.⁷ Gambacorti, C.⁸ Stone, R.M.⁹ Goldman, J.¹⁰ Fischer, T.¹¹ O'Brien, S.G.¹² Reiffers, J.J.¹³ Mone, M.¹⁴ Krahnke, T.¹⁵ Talpaz, M.¹⁶ Kantarjian, H.M.¹⁷

5
- 77954799488
- Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes
- Kantarjian HM, Giles FJ, Bhalla KN, et al: Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes. ASH Annual Meeting Abstracts 114:1129, 2009
- (2009) ASH Annual Meeting Abstracts , vol.114 , pp. 1129
- Kantarjian, H.M.¹ Giles, F.J.² Bhalla, K.N.³

6
- 70249100937
- Nilotinib post-liver transplantation for acute hepatic failure related to imatinib
- Perini GF, Santos FP, Funke V, et al: Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leuk Res 33:e234-e235, 2009
- (2009) Leuk Res , vol.33
- Perini, G.F.¹ Santos, F.P.² Funke, V.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.